Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-01-21 00:00:00 ET · period of report 2026-01-20 · accession 0001283303-26-000001 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-21 | 2026-01-20 | TVTX | REED ELIZABETH E | CLO, GC | S - Sale+OE | $27.34 | -10.0K | 90.3K | -10% | -$273.4K |
| D | 2026-01-21 | 2026-01-20 | TVTX | REED ELIZABETH E | CLO, GC | M - OptEx | $19.08 | +10.0K | 100.3K | +11% | +$190.8K |
| D | 2026-01-21 | 2026-01-20 | TVTX | REED ELIZABETH E | CLO, GC | M - OptEx | $0.00 | -10.0K | 30.0K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-20 | S | D | 10,000 | $27.34 | 90,270 | D | — | — | (F3) The weighted average sale price for the transaction reported was $27.3420, and the range of prices were between $26.910 and $27.590. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 2 | Common | Common Stock | 2026-01-20 | M | A | 10,000 | $19.08 | 100,270 | D | — | — | (F1) Includes 392 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 28, 2025. |
| 3 | Derivative | Employee stock option (right to buy) | 2026-01-20 | M | D | 10,000 | $0.00 | 30,000 | D | $19.08 · — to 2027-01-04 | 10,000 Common Stock | (F4) The stock option is fully vested and exercisable. |